Clinical trials located in

Limburg

Limburg city is located in Germany. Currently, 7 clinical trials are being conducted in this city.

Limburg, nestled in Germany, is renowned for its well-preserved medieval architecture. The city’s centerpiece, Limburg Cathedral (Limburger Dom), is a stunning example of late Romanesque style, dating back to the 13th century. Limburg’s Old Town, with its timber-framed houses, adds to the city’s historical charm. The Lahn River gracefully flows through Limburg, enhancing its picturesque setting. Notably, the city once thrived on the trade route between Frankfurt and Cologne, contributing to its historical wealth and architectural development.

  • CT-EU-00054021

    Improving psoriasis treatment for patients: a study on brodalumab

    This detailed study focuses on individuals with moderate-to-severe plaque psoriasis who weigh more than 120 kg. It aims to find out if adjusting the dose of the medication brodalumab can lead to better skin health. In this study, participants receive either an adjusted higher dose of brodalumab or the standard dose. Researchers closely monitor the skin’s response to the treatment, checking if the adjusted dose leads to better skin clearance, meaning fewer or no psoriasis symptoms.

    • Brodalumab
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Exploring chronic lymphocytic leukemia treatments: acalabrutinib, obinutuzumab, venetoclax in new trial

    This clinical trial compares two drug combinations for treating high-risk chronic lymphocytic leukemia (CLL). It’s a Phase 3 study, focusing on patients who haven’t received prior treatment. Participants will either receive a triple combination of acalabrutinib, obinutuzumab, and venetoclax (GAVe) or a double combination of obinutuzumab and venetoclax (GVe). The main goal is to see if the triple combination can better prolong the time patients live without their disease getting worse, compared to the double combination.

    • Obinutuzumab
    • Acalabrutinib
    • Venetoclax
  • Effectiveness of ivosidenib for advanced cholangiocarcinoma treatment

    This study is about taking a medicine called Ivosidenib to help adults that have been treated before for a serious type of liver cancer known as cholangiocarcinoma. The medicine is taken as a tablet once a day for 28 days, which is known as one cycle. The medicine is already approved for use in the US and Europe, but this study wants to understand better how it works and how it affects patients’ lives. There’ll be at least 6 visits to the doctor for anyone taking part, which include things like heart checks, physical exams, and tests on your blood and urine. After stopping treatment, you’ll have a follow-up visit every 6 months for up to 18 months. If at any point, Ivosidenib becomes available at your local pharmacy, you’ll stop the study and continue using it as a normal medicine. The researchers will keep checking in to see how you’re doing.

    • Ivosidenib
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Germany:

.